Targeted agents for the treatment of metastatic melanoma

Abstract: In the last year, the armamentarium of melanoma therapeutics has radically changed. Recent discoveries in melanoma biology and immunology have led to novel therapeutics targeting known oncogenes and immunotherapeutic antibodies. Phase III clinical trials of these agents have reported measurable and meaningful benefits to patients with metastatic disease. In this article, we review recent findings and discuss their significance in melanoma therapy. As our understanding of melanoma biology grows, this initial therapeutic success may be enhanced through the use of molecular markers to select patients, and new targeted immunotherapies in sequential or combination drug regimens.

Keywords: metastatic melanoma, ipilimumab, vemurafenib, antitumor

Epidemiology and treatment of metastatic melanoma

Malignant melanoma is an important health care issue. The incidence of melanoma has increased dramatically over the last four decades and melanoma is now one of the most common forms of cancer. In 2011, over 75,000 North Americans will be diagnosed with melanoma and over 9000 will die from it.\(^1\)\(^2\) Although less common than cancers of the breast, prostate, or colon, it is potentially more lethal. It has a high propensity for hematogenous and lymphatic dissemination to regional and distant sites and is poorly responsive to most systemic therapies. The 5-year survival rate for metastatic melanoma is dismal, ranging from 5% to 10% with a median survival of less than 8 months with treatment.\(^3\)

Until recently, the therapeutic options for patients with metastatic melanoma were limited. The only approved treatment options were dacarbazine and interleukin 2 (IL-2). Dacarbazine, an alkylating agent, has a response rate of <10%, with median response durations of 4–8 months.\(^4\) Single-agent therapy with IL-2, an immune-modulatory agent, has similar overall response rates of 16%, with ~5% of patients achieving durable complete responses (CRs) that may result in long-term survival in selected patients.\(^5\) Use of IL-2 is limited by its low overall response rate and its potential severe multiorgan toxicities requiring management in specialized cancer centers. With these agents, remissions are infrequent, usually of short duration, and treatment is primarily palliative, as neither agent has been shown definitively to improve survival. Improved treatments with high-risk resected and advanced metastatic disease are urgently needed.

In the last year, there have been major treatment advances for metastatic melanoma patients. Two agents, ipilimumab (Yervoy\textsuperscript{TM}, Bristol-Myers Squibb,
Princeton, NJ) and vemurafenib (Zelboraf, Plexxikon/Roche, Auckland, NZ), have demonstrated improved survival in patients with advanced melanoma when compared with standard treatments. The clinical benefits of these targeted drugs have been realized after decades of research in the molecular pathogenesis of melanoma. This research has identified tumor and immune cellular signaling pathway abnormalities that promote melanoma development and progression. Once regarded as a cancer with a dismal record of negative Phase III treatment trials, melanoma is now a tumor type for the clinical evaluation of paradigm-shifting therapeutic strategies. In this review, we outline key molecular pathways and the agents targeting them.

### Melanoma, the immune system, and immune targeting monoclonal antibodies

There is overwhelming evidence that melanoma is an immune-responsive cancer. Spontaneous regression of melanoma is observed and is probably due to immune processes. The identification of tumor-infiltrating lymphocytes and melanoma antigen-specific T-cells in peripheral blood from cancer patients are evidence that melanoma-specific immune recognition and activation occur. Moreover, melanoma exhibits cellular properties that can be explained by immune selection, such as downregulation of major histocompatibility complex class I expression or release of cytokines such as transforming growth factor-beta. Lastly, dramatic clinical responses have been demonstrated with immune-modulatory treatments, such as IL-2 and adoptive T-cell transfer in selected patients with metastatic melanoma, although neither of these treatments have demonstrated superiority over standard of care in randomized clinical trials. However, ipilimumab, a novel monoclonal antibody modulating the immune system, provides the first evidence that an immunotherapy strategy can change the clinical course of metastatic melanoma and result in improvement in patient survival.

Ipilimumab is a modulator of immune system activation. T-cell activation occurs when an antigen is presented by a major histocompatibility complex molecule and a co-stimulatory molecule, B7.1 or B7.2, binds to CD28. Simultaneously, downregulation of this process is initiated by B7-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) binding. Inhibitory co-receptors and pathways restrict T-cell functions to prevent autoimmunity. In cancer patients, this restraint impedes antitumor immunity. Monoclonal antibodies that bind to CTLA-4 and block the interaction between B7 and CTLA-4 inhibit this negative signal, and may break peripheral tolerance to self-tissues and induce antitumor responses. Ipilimumab is a fully human, IgG1 monoclonal antibody that blocks CTLA-4. By inhibiting CTLA-4, ipilimumab potentiates T-cell activation and proliferation, promoting antitumor immunity. Proof of benefit from the approach is found in two recent randomized controlled Phase III trials that demonstrated improved survival in patients with metastatic melanoma treated with ipilimumab. However, the drug’s effect on the immune response is not tumor specific: ipilimumab treatment has been associated with severe and potentially fatal immunological adverse effects due to T-cell activation and proliferation. A risk evaluation and mitigation strategy has been set up to inform prescribers of the potential risks.

The first ipilimumab Phase III study randomized patients with advanced stage melanoma who progressed on standard treatments, to receive ipilimumab plus gp100 (a melanoma-specific antigen), ipilimumab alone, or gp100 alone. The median overall survival (OS) was statistically superior among patients randomized to an arm containing ipilimumab, as compared with those patients receiving gp100 alone (approximately 10 months versus 6.4 months). No difference in OS was detected between the ipilimumab groups. This was the first study to demonstrate a survival benefit in the setting of advanced melanoma in over three decades, but the enthusiasm was tempered by the lack of a standard treatment in the control arm.

The second Phase III study, conducted in previously untreated metastatic melanoma patients and with an acceptable control treatment arm, corroborated the benefits observed with ipilimumab treatment. This study randomly assigned patients with previously untreated metastatic melanoma to ipilimumab plus dacarbazine or placebo plus dacarbazine. OS was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine alone: 11.2 months versus 9.1 months, respectively. Interestingly, benefit from ipilimumab was seen across patient subgroups based on human leukocyte antigen types, tumor mutations, or prognostic factors such as serum lactate dehydrogenase. This confirmed the clinical benefit of ipilimumab and added to the growing number of immunotherapeutic strategies for patients with advanced melanoma.

These ipilimumab trials demonstrated proof of clinical benefit of immune modulation in metastatic melanoma. Key areas for future research focus on improving the risk–benefit of immunotherapy in metastatic disease and evaluating the agent in high-risk early stage disease. For the
former, efforts focused on the following areas are required: (1) reduction in the frequency and severity and improved management of adverse effects, (2) identification of markers of tumor sensitivity and patient risk of severe side effects, and (3) the evaluation of combination strategies that either increase the tumor-specific immune response and/or target tumor proliferation and survival pathways. For the latter, trials are underway to evaluate the benefit of ipilimumab in resected melanoma patients. Agents and trial results of therapies targeting the immune system are summarized in Table 1. Tumor-targeting drugs are discussed further in the next section.

The molecular pathways altered in melanoma cells
Crucial genetic alterations that enhance the oncogenic potential in melanoma have been identified. Key mutations that lead to constitutive activation of tumor growth and survival pathways occur in the receptor tyrosine kinase CKIT (CD117), and the RAS/RAF/MEK/ERK and phosphoinositide-3-OH kinase (PI3K)/Protein Kinase B (AKT)/phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signal transduction systems (Figure 1). Although convenient to conceptualize these pathways as independent, significant interactions occur and simultaneous activation of the pathways plays a role in melanoma pathogenesis. The demonstration that the mutant BRAF inhibitor vemurafenib improves survival in patients with metastatic melanoma proves that targeting aberrant proteins of signaling pathways with kinase inhibitors can lead to clinical benefit.13 Below, we describe some of these key pathways and the agents designed to target the components of these pathways (see Figure 1).

The RAS/RAF/MEK/ERK pathway
The RAS/RAF/MEK/ERK pathway plays a role in normal organogenesis; however, when aberrantly activated it can lead to malignant cellular proliferation, inhibition of apoptosis, and invasion.14 This mitogen-activated protein kinase (MAPK) pathway relays extracellular signals from the plasma membrane of the cell to the nucleus via an ordered series of phosphorylation events.15 Various extracellular stimuli, including growth factor-mediated activation of receptor tyrosine kinases (RTKs), lead to the sequential recruitment, phosphorylation, and activation of one of three RAS isoforms (designated KRAS, NRAS, HRAS), three RAF family members (ARAF, BRAF, CRAF) via a SRC-family tyrosine kinase,16–18 MEK (mitogen-activated ERK kinase)19–21 and ERK (extracellular signal-regulated kinase).21–23 Activated ERK translocates to the nucleus and phosphorylates several nuclear transcription factors necessary for cellular proliferation, differentiation, and survival.

Constitutive activation of the MAPK pathway occurs in 90% of melanomas.24 The two most common mechanisms for MAPK pathway activation in melanoma are mutations in the BRAF (40%–60%) and NRAS genes (15%–30%).25,26 The BRAF V600E mutation accounts for approximately 90%

| Table 1 | Clinical trials of selected immune modulators in melanoma |
|---------|----------------------------------------------------------|
| **Agent** | **Phase** | **Melanoma patients (n)** | **Observations** | **Reference** |
| **Monoclonal antibodies** | | | | |
| Anti-CTLA-4 tremelimumab | 3 | 655 | Median OS 11.8 months (95% CI 10.4, 13.9) in the tremelimumab arm, and 10.7 months (95% CI 9.3, 12.0) in the chemotherapy arm, HR 1.04 (95% CI 0.84, 1.28) | 126 |
| Anti-PD-1 MDX-1106 | 1 | 10 | 1 PR, 2 MR | 127 |
| Anti-CD137 BMS-663513 | 2 | 47 | 3 PR | 128 |
| **Tumor vaccines** | | | | |
| Recombinant MAGE-A3 fusion protein gp100:209–217(210M) peptide | 2 | 75 | 3 responses | 129 |
| | 3 | 185 randomized to IL-2 versus IL-2 + GP100 | Overall RR 22.1% vs 9.7% (P = 0.0223) | 130 |
| | | | PFS 2.9 months (1.7–4.5) vs 1.6 (1.5–1.8) (P = 0.0101) | |
| OncoVEXGM-CSF* | 2 | 43 | 6 CR, 6 PR, 7 SD of injected tumors | 131,132 |

**Note:** *An oncolytic herpes simplex virus vector encoding granulocyte monocyte colony-stimulating factor (GM-CSF).*

**Abbreviations:** CTLA4, cytotoxic T-lymphocyte-associated antigen 4; PD-1, programmed death-1; IL-2, interleukin 2; OS, overall survival; PFS, progression free survival; RR, response rate; HR, hazard ratio; PR, partial response; MR, minor response; CR, complete response; SD, stable disease.
of all activating \textit{BRAF} mutations. This protein product of the \textit{V600E} mutation has demonstrated a 10.7-fold increase in kinase activity as compared with the wild-type protein. Constitutive activation of \textit{BRAF} and the MAPK pathway impart a proliferative and survival advantage to the cancer cell. Mutations in \textit{ARAF} and \textit{CRAF} have not been found in melanoma. Vemurafenib is a potent inhibitor of the activated \textit{V600E BRAF} mutant protein and wild-type \textit{BRAF}, but is a weak inhibitor of the A and CRAF isoforms.

The second most common means for MAPK pathway activation in melanoma is through mutations in the \textit{NRAS} gene. Somatic \textit{RAS} mutations usually occur in codons 12, 13, or 61 and maintain \textit{RAS} protein in a constitutively active state. Mutations in the \textit{HRAS} and \textit{KRAS} isoforms are rare in melanoma. Interestingly, \textit{BRAF} and \textit{RAS} activating mutations are often mutually exclusive events, suggesting only one mutation within the same pathway is sufficient for pathway activation and denoting the redundant mechanisms of activating this pathway in melanoma pathogenesis. Of note, oncogenic \textit{RAS} can also bind and activate \textit{PI3K}, resulting in increased \textit{AKT} activity. Thus, \textit{RAS} activation leads to the upregulation of two major signaling cascades involved in melanoma: the MAPK and PI3K/\textit{AKT}/mammalian target of rapamycin (mTOR) pathways. The mechanism of pathway activation and molecular response to specific targeted inhibition are likely to be determinants of sensitivity and clinical benefit to individual agents and combinations.

**PI3K/\textit{AKT}/mTOR pathway**

The PI3K/\textit{AKT}/mTOR pathway is another signaling transduction pathway that is aberrantly activated in several cancers, including melanoma. In response to activated RTKs, the PI3K phosphorylates phosphatidylinositol-4,5-biphosphate to phosphatidylinositol-3,4,5-triphosphate (PIP3), recruiting other proteins to the plasma membrane and leading to activation of the major downstream effector of the PI3K pathway, \textit{AKT}. Once active, \textit{AKT} phosphorylates a number of substrates that promote cell survival, proliferation, and invasion. One substrate is the mTOR, a serine threonine kinase that modulates protein synthesis, angiogenesis, and cell cycle progression and validated therapeutic target in renal cell carcinoma, neuroendocrine tumors, and lymphoma.

Although activating mutations in PI3K are rare, downstream effectors PTEN and \textit{AKT}, are altered in the majority of melanomas. The tumor suppressor gene \textit{PTEN} encodes a lipid and protein phosphatase that negatively regulates the PI3K cascade through dephosphorylation of PIP3. Decreased or loss of PTEN expression or function through epigenetic silencing, inactivating mutation or deletion is observed in 30%–60% of primary melanomas. The tumor suppressor gene \textit{PTEN} occurs in association with \textit{BRAF}, but not \textit{NRAS} mutations suggesting the dual pathway activation can be accomplished by alterations in \textit{NRAS} alone or the combination of \textit{PTEN} and \textit{BRAF}. In contrast, \textit{AKT} is an oncogene that encodes a kinase that is frequently activated in human cancers. There are three AKT isoforms and AKT3 is the major isoform deregulated in melanoma. Overexpression of phospho-AKT, typically associated with increased gene copy number, is seen in a greater proportion of melanomas and melanoma metastases than nevi and may be associated with earlier progression and shorter survival of patients with melanoma. Inhibition of AKT3 using small interfering RNA or increased activation of PTEN stimulated apoptosis of melanoma cell lines, indicating a prosurvival function of AKT in melanoma. In vitro cell line and in vivo mouse xenograft studies of simultaneously targeting AKT3 and \textit{V600E BRAF} with small interfering RNAs led to increasing cellular apoptosis and decreasing proliferation supporting the relevance of both pathways in melanoma.
c-KIT

c-KIT (also known as CD117) is a RTK that also contributes to the pathogenesis of a subset of melanomas that do not harbor NRAS or BRAF mutations. c-KIT activates several signaling cascades, including the MAPK, PI3K/AKT/mTOR, and microphthalmia associated transcription factor pathways. c-KIT signaling is necessary for differentiation, proliferation, and migration of normal melanocytes. c-KIT alterations is reported to be lower in Chinese, Korean, and Australian cohorts compared to Western patients. c-KIT mutations and/or copy number increases were identified in the melanomas from mucosa, acral and chronic sun-induced damaged skin. Point mutations in this gene result in constitutive activation of downstream effectors of key signaling pathways in melanoma cells. Although the frequency of c-KIT alterations is reported to be lower in Chinese, Korean, and Australian cohorts compared to Western patients, such aberrations have been identified in Chinese patients with nonchronic sun-damaged skin and melanomas of unknown primary. Geographical variability in predisposing risk factors, small study sample sizes, incomplete testing of the c-KIT gene, and differing criteria for solar elastosis, the marker of chronic sun-damage may explain the apparent variation on KIT mutation frequencies between populations.

The above laboratory and clinical studies support the importance of activating c-KIT and components of the PI3K and MAPK pathways for melanoma pathogenesis. Based on this evidence, activation may occur through NRAS mutations that activate both the PI3K and MAPK pathways, or concurrent BRAF mutations with altered function of either PTEN or AKT, or through c-KIT mutations. Although these are not the sole alterations that contribute to melanoma pathogenesis, the clinical and laboratory results provide the initial rationale for testing specific agents and combinations in melanoma patients.

Potential targeted treatments for patients with advanced melanoma

Agents targeting the MAPK pathway

Agents targeting the MAPK pathway are the first small molecule kinase inhibitors to demonstrate clinical benefit for melanoma patients. Agents that have entered into clinical testing can be grouped into those that are relatively specific for BRAF and/or mutant BRAF, nonspecific RAF inhibitors, and MEK inhibitors. Clinical trials of agents within these classes show varying activity and toxicity that may be due to the pharmacology of the individual agents (ie, specificity and potency of target inhibition) and to the specific tumor molecular profile of patients. Pharmacodynamic studies suggest that >80% inhibition of ERK is needed for clinical activity. Common adverse events are rash, fatigue, nausea, and diarrhea. Specific toxicities include the development of cutaneous keratoacanthoma or squamous-cell carcinoma with specific BRAF inhibitors, and retinal toxicity (central serous retinopathy and retinal vein occlusion) with MEK inhibitors.

Laboratory results suggest there are feedback loops within the MAPK system of biological and clinical relevance and that genotype may determine the activity of specific agents. For instance, the development of borderline and malignant skin tumors such as keratoacanthomas and squamous-cell carcinomas associated with BRAF inhibitors, is thought to arise due to paradoxical MAPK signaling in cells with wild-type BRAF. Clinical studies show that inhibition of wild-type RAF leads to upregulation of RAS signaling and ERK activation. Moreover, the results of three studies suggest that inhibitors thought to be selective for mutant BRAF can also activate CRAF through the formation of dimeric RAF complexes – a process that is enhanced by the presence of an oncogenic RAS mutation. These studies support the conclusion that mutant-specific BRAF inhibitors should be used for treating cancers caused by BRAF mutants (such as BRAF V600E-associated melanomas), but should not be used as single agents in melanomas (and other cancers) with RAS mutations as they may promote tumor genesis. Such mechanistic insight into both normal and pathogenic MAPK signaling suggest that certain agents and combinations may be preferable in certain molecular contexts and lead to the development of effective new anticancer therapies.

Selective mutant BRAF-inhibitor vemurafenib

Vemurafenib (PLX-4032, RG7204) is an inhibitor of a mutant form of the BRAF kinase and the second agent, after ipilimumab, to improve OS in patients with advanced melanoma. In the Phase III study, named BRIM 3 (BRAF Inhibitor in Melanoma 3), previously untreated patients with advanced melanoma that harbored the V600E mutation, were randomized to either vemurafenib or dacarbazine. A significant improvement in 6-month OS was observed in the vemurafenib group versus the dacarbazine group (84% versus 64%, respectively). In the interim analysis for OS and final analysis for progression-free survival (PFS), vemurafenib was associated with a significant relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression compared with dacarbazine. Common adverse events associated with vemurafenib were...
arthralgia, rash, fatigue, alopecia, photosensitivity, nausea, and diarrhea. Cutaneous squamous-cell carcinoma, kerato- canthoma, or both developed in 18% of patients. All lesions were treated by simple excision. This trial was the first to show that a rationally targeted agent improved survival by inhibiting an aberrantly overactive signaling pathway in melanoma.

**Resistance to vemurafenib**

Despite the benefits observed with vemurafenib, both intrinsic and acquired resistance has been observed in patients with advanced melanoma. Emerging evidence suggests that resistance to vemurafenib is complex and multifactorial. Preclinical studies suggest that PTEN loss, C-RAF mutations, or Cot-1 mutations may confer intrinsic resistance to vemurafenib.\(^6^2,6^3\) Vemurafenib-mediated apoptosis was significantly impaired in PTEN negative melanoma cell lines.\(^6^3\) Moreover, screening for kinases that prevented vemurafenib-mediated cell growth arrest identified both CRAF and Cot1 as potential drivers of resistance.\(^6^2\) Both CRAF and Cot 1 bypass BRAF signaling, activating the MAPK pathway. Although these studies may make mechanistic sense, no study has demonstrated that pre-existing alterations in PTEN, CRAF, or Cot-1 predict for intrinsic resistance to vemurafenib.

In attempts to identify the genetic changes that lead to acquired resistance to vemurafenib, researchers have compared matched tumor samples from patients prior to treatment and after treatment failure. Cot-1 mRNA levels, and insulin-like growth factor receptor-1 and platelet-derived growth factor receptor (PDGFR) immunohistochemistry staining have all been found to be elevated in post-treatment samples when compared to pretreatment biopsies.\(^5^2,6^4,6^5\) Moreover, RAS or MEK activating mutations, that were not present in the pre-treatment tumor, have been identified in tumors from patients progressing on vemurafenib treatment.\(^5^4,6^6\) A common theme in these mechanisms of resistance is the restoration of MAPK signaling and/or an increase in PI3K/ AKT/mTOR signaling, emphasizing the importance of these pathways on melanoma progression. By understanding the molecular events that lead to resistance, rational combinations or subsequent treatments can be designed.

**Other selective BRAF inhibitors**

Selective inhibitors of BRAF are in development including SB90885, GDC-0879, and GSK2118436 (GSK436). The most detailed clinical information is available for the latter and is summarized in the next column.

**GSK436**

GSK436 is a highly potent and selective adenosine-5’-triphosphate (ATP)-competitive BRAF inhibitor. The selectivity of this agent for mutant BRAF is over 100 times greater than the wild-type protein.\(^6^7\) It displays dose-dependent inhibition of MEK and ERK phosphorylation in mutant BRAF cell lines and tumor regression in xenograft models.\(^6^8\) In the first-in-human Phase I study, 61 patients (57 with BRAF mutations) had been accrued and the maximum tolerated dose had not yet been determined by the time the study was reported (see Table 2).\(^6^9\) In patients with mutant BRAF melanoma, a response rate of 63% (10 of 16 patients) was observed in the patients receiving doses ≥150 mg twice a day. Cohorts receiving lower doses had a response rate of 39% (26 of 41 patients, one CR, and 25 partial responses [PRs]). The probability of response to GSK436 directly correlated with the presence of a BRAF mutation and inversely with the presence of a PTEN alteration. Due to its high response rate and reasonable toxicity profile, GSK436 is being evaluated in combination with the MEK inhibitor GSK1120212 in an attempt to enhance the clinical activity (discussed further below).

**Nonselective BRAF inhibitors**

**Sorafenib**

Sorafenib is a small molecule inhibitor of multiple kinases, including wild-type BRAF, V600E BRAF, and CRAF as well as vascular endothelial growth factor receptors (VEGFR) and PDGFR.\(^6^9,7^0\) Inhibition of the MAPK pathway has been demonstrated in vitro and in vivo with this agent. Sorafenib has limited single agent activity in patients with melanoma.\(^7^1,7^2\) Although interesting clinical activity was reported from a Phase II trial of sorafenib combined with carboplatin and paclitaxel,\(^7^3\) the Phase III trials testing this combination in the first- and second-line settings did not show improvements in response rate, PFS, or OS (Table 2).\(^7^4,7^5\) Currently, clinical investigations are focused on combining sorafenib with other targeted, immunomodulatory, and chemotherapy agents (see Table 3).

**RAF265**

RAF265 is also a multitargeted small molecule inhibitor of both the V600E BRAF mutant and VEGFR. A Phase I trial treating advanced melanoma patients with RAF265 demonstrated an overall response rate of 16% (6 of 37 patients) for BRAF mutation-positive melanoma patients and 13% (4 of 30) for wild-type or BRAF mutation status unknown patients (see Table 2).\(^7^6\) Because of dose limiting hematologic
toxicity, an intermittent schedule will be explored in an effort to improve the therapeutic index. Whether this agent offers particular advantage over more selective and effective BRAF inhibitors, such as vemurafenib and GSK2118436, will be determined in future clinical trials.

**MEK inhibitors**

MEK is an attractive therapeutic target as it is downstream of both activated BRAF and NRAS. Preclinical studies suggested that melanoma cell lines with mutant BRAF were more sensitive to MEK inhibition than those harboring activating NRAS mutations and wild-type BRAF genes. Small-molecule inhibitors of MEK completely abrogated tumor growth in BRAF mutant xenografts, whereas RAS mutant tumors were only partially inhibited. Agents that entered clinical development include CI-1040, PD-0325901, GSK1120212, and AZD6244. The activity of first- and second-generation MEK inhibitors CI-1040 and PD-0325901 has been limited by pharmacologic and toxicity issues. CI-1040 was an agent that was generally tolerated well, but it failed to demonstrate sufficient anticancer activity to warrant further development. PD-0325901 is structurally similar to CI-1040, but is more potent at MEK inhibition and has greater systemic exposure. In Phase I trials, melanoma patients achieved objective responses, and suppression of phosphorylated ERK in melanoma specimens. However, clinical development was terminated because of unexpected high incidence of musculoskeletal and neurological adverse events (see Table 2). Newer MEK inhibitors such as GSK1120212 appear to have greater potency and have demonstrated promising clinical activity, particularly in tumors with BRAF mutations.

**GSK1120212**

GSK1120212 (GSK212) is a reversible, selective allosteric inhibitor of both MEK1 and MEK2. Preclinical studies have demonstrated that it can inhibit the phosphorylation of ERK and had growth inhibition in a variety of cancer cell lines. The first-in-human Phase I study of GSK212 determined the recommended Phase II dose to be 2 mg daily (see Table 2).

### Table 2 Clinical trials of single-agent kinase inhibitors in melanoma

| Agent                  | Phase | Number of melanoma patients evaluable for response (n) | Response observed in melanoma patient(s) | Reference |
|------------------------|-------|--------------------------------------------------------|-----------------------------------------|-----------|
| c-KIT inhibitors       |       |                                                        |                                         |           |
| Imatinib               | 2     | 16                                                     | No objective responses                   | 103       |
| Imatinib               | 2     | 21                                                     | 1 PR, 4 SD                              | 102       |
| Imatinib               | 2     | 25                                                     | No objective responses, 2 SD             | 104       |
| Imatinib               | 2     | 43 c-KIT positive                                     | 10 PR, 13 SD, mPFS = 3.5 months, 6 months, PFS rate = 36.6% | 101       |
| Imatinib               | 2     | 25                                                     | 2 CR, 4 PR                              | 100       |
| Dasatinib              | 2     | 36                                                     | 2 PR                                    | 105       |
| Multi-target BRAF inhibitors |   |                                                        |                                         |           |
| Sorafenib              | 2     | 30                                                     | 0 CR, 0 PR, 7 SD, 23 PD                 | 72        |
| RAF265 (CHIR-265)      | 1     | 76                                                     | The overall response rate by RECIST 1.0 was 6/37 (16%) for mut BRAF pts and 4/30 (13%) for wt (3)/unknown (1) BRAF pts | 76        |
| Selective BRAF inhibitors |   |                                                        |                                         |           |
| GSK2118436             | 1/2   | 57 BRAF mutation positive                             | 1 CR, 25 PR                             | 68        |
| MEK inhibitors         |       |                                                        |                                         |           |
| PD-0325901             | 1     | 48                                                     | 0 CR, 3 PR, 10 SD                       | 78        |
| PD-0325901             | 1     | 7                                                      | 1 CR                                    | 79        |
| GSK1120212             | 1     | 42                                                     | BRAF mutation positive: 2 CR, 6 PR      | 81        |
|                        |       |                                                        | BRAF wt: 2 PR                           |           |
| AZD6244                | R2    | 104                                                    | 6 PR                                    | 83        |
| AKT inhibitors         |       |                                                        |                                         |           |
| Perifosine             | 2     | 14                                                     | 0 CR, 0 PR                              | 86        |
| mTOR inhibitors        |       |                                                        |                                         |           |
| Temsirolimus           | 2     | 33                                                     | 1 PR                                    | 91        |
| Everolimus             | 2     | 53                                                     | 2 PR                                    | 92        |

**Abbreviations:** OS, overall survival; PFS, progression free survival; HR, hazard ratio; RR, response rate; PR, partial response; MR, minor response; CR, complete response; SD, stable disease; mut, mutant; wt, wild-type; pts, patients.
Common toxicities were grade 1 and 2 rash and diarrhea. There were three cases of reversible central serous retinopathy. Seventy-two of 162 patients enrolled in the study had advanced melanoma. Of the patients with melanoma, 24 tumors harbored \textit{BRAF} mutations, 24 had a wild-type \textit{BRAF} gene, and 22 had an unknown \textit{BRAF} status. There were two CRs and six PRs among 20 evaluable patients with \textit{BRAF} mutant melanoma for a preliminary objective response rate of 40%. In contrast, two of 22 evaluable patients with \textit{BRAF} wild-type melanomas had PRs. These results suggest that response correlates with \textit{BRAF} mutation status. Activity in some \textit{BRAF} wild-type melanoma tumors suggest that these are also dependent on the MAPK pathway by mechanisms unrelated to most common \textit{BRAF} mutations. Trials of drug combinations are currently being tested to improve the efficacy of this agent.

**AZD6244**

AZD6244 (formerly called ARRY-142886) is a selective non-ATP competitive inhibitor of MEK1 and MEK2.\textsuperscript{82} In a Phase II trial, 210 patients with advanced melanoma were randomly allocated to AZD6244 or temozolomide (see Table 2).\textsuperscript{83} Although there was no significant difference in the primary endpoint of PFS between the two arms, five of six patients with PRs from AZD6244 had \textit{BRAF} V600E-mutated tumors. The activity observed warrants further investigation of this agent in combination with other drugs in selected patients.

### Table 3 Clinical trials of combinations in melanoma

| Agent                  | Combination                  | Phase | Melanoma patients evaluable for response (n) | Response or endpoints observed in melanoma patient(s) | Reference |
|------------------------|------------------------------|-------|---------------------------------------------|-------------------------------------------------------|-----------|
| **Multi-target BRAF inhibitors** |                             |       |                                             |                                                       |           |
| Sorafenib              | Interferon alpha             | I     | 1 with the remaining 12 being renal cell cancer | 1 SD                                                  | 133       |
| Sorafenib              | Pegylated Interferon alpha   | 2     | 41                                           | 3 PR, 14 SD                                           | 134       |
| Sorafenib              | Dacarbazine                  | R2    | 51 in the sorafenib and dacarbazine arm      | CR + PR = 12 There were statistically significant improvements in PFS rates at 6 and 9 months, and in TTP in favor of the sorafenib plus dacarbazine arm. No difference in OS was observed | 135       |
| Sorafenib              | Dacarbazine                  | 2     | 74                                           | 0 CR, 8 PR, 34 SD, 32 PD                               | 136       |
| Sorafenib              | Carboplatin and Paclitaxel   | 1/2   | 34                                           | 11 PR, 19 SD                                         | 73        |
| Sorafenib in the first-line setting | Carboplatin, and Paclitaxel | 3     | 409 pts on the sorafenib, carboplatin, and paclitaxel arm | No difference in OS, PFS, or RR | 74        |
| Sorafenib in the second-line setting | Carboplatin, and Paclitaxel | 3     | 135 pts in both arm                         | No difference in OS, PFS, or incidence of best response | 75        |
| Sorafenib              | Temsirolimus                 | I     | 23                                           | 0 CR, 0 PR, 10 SD                                    | 112       |
| Sorafenib              | Tipifarnib                   | I     | 7                                            | 0 CR, 0 PR, 3 SD                                     | 118       |
| Sorafenib              | Temsirolimus or Tipifarnib   | R2    | Arm A – Sorafenib and temsirolimus arm:66 Arm B – Sorafenib and tipifarnib |                                                       |           |
| **Selective BRAF inhibitors** |                             |       |                                             |                                                       |           |
| GSK2118436             | GSK1120212                   | 1/2   | No prior BRAF inhibitor: 71 Prior BRAF inhibitor: 24 | Without prior BRAF inhibitor: 5 CR, 44 PR, 22 SD. Prior BRAF inhibitor: 0 CR, 3 PR | 125       |
| **VEGF inhibitor**     |                             |       |                                             |                                                       |           |
| Bevacizumab            | Everolimus                   | 2     | 57                                           | 1 CR, 6 PR, 33 SD                                    | 122       |
| Bevacizumab            | Ipilimumab                   | 1     | 22                                           | 1 CR, 6 PR, 7 SD                                     | 123       |

**Abbreviations:** OS, overall survival; PFS, progression free survival; HR, hazard ratio; RR, response rate; PR, partial response; MR, minor response; CR, complete response; SD, stable disease; mut, mutant; pts, patients.
The activity of MEK inhibitors in some patients with \textit{BRAF} wild-type melanomas seen with GSK212 and AZD6244 suggest that there are other mechanisms determining sensitivity to MEK inhibition. Results from laboratory studies evaluating inhibitors across multiple cell line panels indicate that MEK inhibitor activity does not absolutely correlate with the mutational or phosphorylation status of BRAF, MEK, RAS, or PI3K. This lack of correlation has fueled efforts to develop expression profiles of MEK activation and sensitivity. An 18-gene expression signature of MEK activation and inhibition derived from multiple tumor cell lines and xenografts may correlate with sensitivity and be used as a marker of pharmacodynamics response to MEK inhibition. A 13-gene signature was also identified that was predictive of resistance to a MEK inhibitor in cancer cells, despite these cells having functional MEK activity. These signatures potentially may be used to select patients sensitive and resistant to MEK inhibition.

\textbf{Agents targeting the PI3K/AKT/mTOR pathway}

In contrast to the clinical benefits seen with agents targeting the MAPK pathway tested in melanoma patients, the results from clinical trials evaluating agents targeting the PI3K/AKT/mTOR pathway have been disappointing. There are a number of potential explanations for the lack of activity: (1) suboptimal pharmacology and target modulation of the agents at maximum tolerable doses, (2) relative lack of importance of the pathway as a driver of melanoma cell proliferation or survival, (3) intrinsic or rapid onset of acquired resistance to target inhibition, or (4) failure to enrich enrollment into trials for patients likely to benefit. Unfortunately, not all trials have incorporated pharmacodynamics assessment of target inhibition in tumor or surrogate tissue nor employed patient enrichment strategies, thus further evaluation of emerging agents targeting the pathway with better pharmacology is warranted. Descriptions of agents and results from clinical trials are provided in the following sections.

\textbf{AKT inhibitors}

PI3K/AKT/mTOR pathway is another signaling transduction pathway that is aberrantly activated in melanoma and pharmacological inhibition may also benefit patients with melanoma. Although a number of PI3K inhibitors are in clinical development and may have activity in \textit{PTEN} mutant tumors, inhibiting downstream targets AKT or mTOR may be preferable due to the frequency of AKT amplification in melanomas. Despite this finding, the activity of AKT inhibitors perifosine and GSK2141795 as single agents in the treatment of advanced melanoma has been disappointing. These initial results may be due to issues of pharmacology of the individual agents and lack of optimal target inhibition in tumor due to off-target or target-specific toxicity-limiting doses.

\textbf{Perifosine}

Perifosine is an AKT and PI3K inhibitor and structurally related to miltefosine. It interferes with the recruitment of proteins with the pleckstrin homology domain, like AKT, to the plasma membrane. A Phase II study of perifosine treatment in previously untreated patients with metastatic melanoma was conducted and of 14 evaluable patients, none achieved an objective response (see Table 2). The extent of AKT or MAPK pathway inhibition was not evaluated in this study. The authors recommended that no further development of single agent perifosine was required in metastatic melanoma patients.

\textbf{GSK2141795}

GSK2141795 (GSK795) is a reversible, selective ATP-competitive inhibitor of all AKT isoforms. Preclinical studies had demonstrated that GSK795 could inhibit proliferation of cancer cell lines. A Phase I trial has been conducted with GSK795 to determine the recommended Phase II dose, pharmacokinetics, pharmacodynamics, and safety of the drug. In total, 76 patients were enrolled. In the 54 patients evaluable for response, one PR was observed in a patient with metastatic anal cancer, two patients with endometrial cancer had prolonged stable disease (SD) and minor tumor responses in a population selected for molecularly defined predictive signatures (\textit{PTEN} loss or \textit{PIK3CA} mutations). No responses were observed in the patients with melanoma, although few were enrolled in this study.

\textbf{mTOR inhibitors}

Inactivating \textit{PTEN} mutations are identified in 50% of melanomas. The resulting increase in activity of mTOR is believed to derail the normal control of nutrients leading to excessive cell growth and proliferation. However, the results from early Phase clinical trials testing mTOR inhibitors and rapamycin derivatives, temsirolimus and everolimus, in melanoma patients have also shown limited single agent activity.

\textbf{Temsirolimus}

Temsirolimus is an intravenous mTOR kinase inhibitor and ester derivative of rapamycin. When bound to FK506
binding protein, it interacts and inhibits the mTOR kinase activity, resulting in inhibition of the cell cycle. Preclinical studies of temsirolimus demonstrated that it could inhibit tumor activity in a variety of cancers including melanoma cell lines and animal models. A Phase II trial of temsirolimus was conducted in patients with metastatic melanoma (see Table 2). Thirty-three patients were treated with only one patient experiencing a PR lasting 2 months. The median time to disease progression was 10 weeks. Of note, the dose/schedule used in this trial is not the maximum tolerated dose and target inhibition in tumor was not evaluated in this trial. Whether antitumor activity would be greater with higher doses is an unanswered question.

**Everolimus**

Everolimus is an oral mTOR inhibitor. A two-stage Phase II trial was conducted in 29 patients with metastatic melanoma (see Table 2). By the first interim analysis, the activity of everolimus looked favorable with 35% of patients experiencing SD at 16 weeks. The median PFS and OS were just over 3 months and 12 months, respectively. To further investigate the activity of everolimus, the enrollment of a second cohort treated with a higher dose was conducted. An interim analysis of the second cohort found the median PFS and OS was just under 2 months and 9.5 months respectively, tempering the enthusiasm generated by the activity observed in the first cohort. Of the 53 patients enrolled in total, two patients had unconfirmed PRs. The authors concluded that everolimus as a single agent had insufficient activity in metastatic melanoma patients. The reason as to why patients treated at the lower dose had longer survival compared with those treated at higher doses is unknown.

**c-KIT inhibitors**

Three commercially available, orally administered small molecule tyrosine kinases inhibitors, imatinib, dasatinib, and nilotinib, are under evaluation in melanoma. While all three agents inhibit c-KIT, PDGFR, and BCR-ABL, they differ in potency of inhibition, cellular uptake, mechanism interaction with kinase, and overall inhibitory profile for other cellular kinases. The three agents were initially approved for the treatment of patients with chronic myelogenous leukemia which results from the translocation product BCR-ABL. Both imatinib and dasatinib have demonstrated activity in gastrointestinal stromal tumors, which harbors activating mutations in c-KIT or PDGFR. Results suggest that these agents may have activity in c-KIT mutated and, possibly, c-KIT amplified melanomas.

**Imatinib mesylate**

Five Phase II trials of single agent imatinib have been conducted (see Table 2) and the results of these trials demonstrate the importance of patient selection based on the presence of mutations in tumors. Across three trials conducted in patients with mostly nonchronically sun-damaged melanomas and not requiring c-KIT mutation for enrollment, only one of 65 patients achieved a PR, and that patient had a c-KIT mutation-positive acral melanoma. In contrast, two published Phase II studies that required patients to harbor melanomas with c-KIT mutations reported dramatically different results. Across these two studies, there were two CRs and 14 PRs among 65 evaluable patients, for a response rate of almost 25%. Responses were seen in melanomas with c-KIT mutations with known functional relevance. Mutations in c-KIT exons 11 and 13 seemed to correlate better with response than either amplifications or c-KIT overexpression assessed by immunohistochemistry. These promising results with imatinib in this molecular subgroup of melanoma patients warrant confirmation in a prospective randomized trial.

**Dasatinib**

A Phase II study in a molecularly unselected population of advanced melanoma patients has recently been published (see Table 2). Of the 36 patients evaluable for response, two had a PR lasting 24 weeks or more. One of these patients was found to have a c-KIT mutation. The other responder had a wild-type c-KIT gene, but amplification of c-KIT was not tested in this study. The activity of the drug in patients with melanomas likely to carry c-KIT aberrations is currently being evaluated.

**Nilotinib**

Nilotinib is a second-generation tyrosine kinase inhibitor of c-KIT, PDGFR, and BCR-ABL. Nilotinib has similar potencies against c-KIT and PDGFR compared to imatinib. However, the agents differ with respect to cellular transport, where imatinib is transported actively and nilotinib is transported passively. Due to this passive diffusion, nilotinib may achieve higher intracellular concentrations and be subject to less extrinsic resistance mechanism as compared with imatinib. Several Phase II studies are currently recruiting patients with melanomas from acral, mucosal, and chronically sun-damaged skin or melanomas that harbor c-KIT aberrations.
New treatment paradigm for advanced melanoma

Ipilimumab and vemurafenib are poised to become the therapy of choice for patients with previously untreated advanced melanoma. The initial treatment for patients with tumors that harbor the \( \text{BRAF V600E} \) mutation will be vemurafenib, while those patients harboring wild-type \( \text{BRAF} \) tumors will be treated with ipilimumab. However, despite the advances observed with these agents, both intrinsic and acquired resistance has been observed and no standard second-line treatment has been established. Hence, further research into the molecular predictors and mechanisms contributing to resistance will aid in the design of rational treatment combinations and regimens to employ after treatment failure. Research into the molecular pathogenesis of melanoma and its dependence on particular signaling cascades will aid in these efforts.

Combinations of targeted agents in melanoma

Intrinsic and acquired resistance to novel targeted agents is likely due, in part, to the cross talk that occurs between the pathways required for melanoma development and progression. Coordinated blockade of multiple pathways with combinations of targeted agents will hopefully lead to improved treatment efficacy. With the goal of overcoming resistance and enhancing clinical efficacy, a Phase I/II trial is opening soon evaluating the combination of ipilimumab and vemurafenib in subjects with metastatic melanoma and the mutant form of \( \text{BRAF} \) (clinicaltrials.gov identifier: NCT1400451). Other combinations of targeted agents are currently in varying phases of development. Combination strategies have focused on: (1) inhibiting additional targets within the same pathway or (2) inhibiting a different pathway or cellular process that are involved in the pathogenesis or drug resistance of melanoma. Trials combining CTLA4 and other immunomodulatory antibodies, and/or vaccines are also underway. In general, vaccine development strategies may benefit most from combinations with novel immunomodulating monoclonal antibodies. These strategies are based on our current understanding of melanoma targets/pathways, availability of the agents, and limited preclinical experiments that suggest at least additive efficacy of the combination. Results to date suggest that activity of a combination is related to obtaining effective inhibition of the individual targets without inducing significant additional normal tissue toxicity.

Inhibiting targets in parallel pathways

Sorafenib and temsirolimus

As single agents, sorafenib and temsirolimus have modest antimelanoma activity; however, these agents inhibit targets within the parallel signaling pathways and have limited overlapping toxicities. Hence the combination of sorafenib and temsirolimus was expected to produce at least additive activity and have a tolerable side effect profile. The results of a Phase I study of a combination of sorafenib and temsirolimus in patients with advanced melanoma did not meet these expectations (see Table 3).\(^{112} \) Dose escalations of the individual agents were impeded by higher than expected rates of toxicity. There were no responses among 23 evaluable patients, although ten patients had SD of 8–24 weeks. The combination did have effects on target modulation, as both phosphorylated MEK and AKT decreased from pre- and on-treatment tumor biopsies. However, there was no trend in the change of phosphorylated ERK with the combination treatment. The reason for the decrease in phosphorylated MEK and not ERK is unknown, but probably speaks to the complexity of crosstalk amongst these pathways and challenges of assessing pharmacodynamics markers in clinical trials.

Sorafenib and tipifarnib

The frequency of activating \( \text{RAS} \) mutations in melanoma and most cancers suggest that it would be an ideal target for inhibition. Unfortunately, no direct inhibitor of \( \text{RAS} \) has been developed, as it lacks an accessible small molecule binding site. One strategy indirectly inactivates \( \text{RAS} \) function by inhibiting the post-translational modifications required for the full biological activity of \( \text{RAS} \). \( \text{RAS} \) undergoes farnesylation to associate with the plasma membrane and is subsequently activated.\(^{113} \) Inhibitors targeting farnesyl transferase, the enzyme that catalyzes this modification, have been developed and tested in patients with advanced melanoma. The majority of farnesyl transferase inhibitors have limited activity as single agents and in combination with chemotherapy in melanoma patients.\(^{114–117} \) However, several trials combining farnesyl transferase inhibitors with other targeted agents in patients with melanoma are underway. A Phase I trial evaluating the combination of the farnesyl transferase inhibitor, tipifarnib with sorafenib in patients with advanced malignancies has been reported (see Table 3).\(^{118} \) Evidence of target modulation was seen in a quarter of patients with a 50% or more reduction in farnesyl transferase levels. Three of seven
melanoma patients had SD. One patient with prolonged SD had a PDGFR mutation. It is unknown whether the observed response was due to sorafenib, which is known to inhibit PDGFR, or the combination of both agents.

Another randomized Phase II trial in molecularly unselected metastatic melanoma patients tested the combinations of sorafenib and temsirolimus (Arm A) or sorafenib and tipifarnib (Arm B) (see Table 3).119 Significant toxicity limiting dose escalation was seen with both combinations. Among 66 evaluable patients in Arm A, there were three PRs (5%) and 24 SD (36%). Of the 42 evaluable patients in Arm B, there was one PR (2%) and ten SDs (24%). Based on these results, neither combination appear to show sufficient activity for further evaluation, possibly due to poor pathway inhibition at tolerated doses.

**Bevacizumab and everolimus**

Vascular endothelial growth factor (VEGF) is frequently overexpressed in melanoma and high levels of VEGF may represent an adverse prognostic feature.120 Aberrant activity of the VEGF pathway results in tumor angiogenesis and monocyte/macrophage migration. Concurrent inhibition of tumor and endothelial cell proliferation by combining a VEGF inhibitor with an mTOR inhibitor like everolimus, which also down regulates the VEGF receptor may be efficacious. The combination of the VEGF monoclonal antibody bevacizumab and everolimus has activity in metastatic clear cell renal carcinoma.121 A Phase II study involving 57 patients with metastatic melanoma evaluated the efficacy and safety of bevacizumab and everolimus. Seven patients (12%) experienced objective responses (1CR, 6PR) and 33 had SD (58%) (see Table 3).122 The median PFS and OS were 4 months and 8.6 months, respectively. This activity is greater than expected for the individual agents and the researchers recommended further exploration of these agents in other combinations.

**Ipilimumab and bevacizumab**

The activity of immunological therapies may in part be related to damage to the tumor vasculature. Ipilimumab induces a hemorrhagic necrosis of tumors that is likely due in part to immune mediated vasculopathy.123 Similar changes are observed in metastases of patients with durable clinical responses to CTLA-4 antibody blockade and vaccination with irradiated autologous tumor cells engineered to secrete GM-CSF.124 In these patients, high titer antibodies are produced against VEGF, suggesting ipilimumab and other immunotherapy may induce host responses that target angiogenic networks in the tumor microenvironment. In addition, VEGF not only affects tumor microenvironment, it also potently inhibits the maturation of antigen presenting cells and thus may contribute to the ability of tumors to evade the host immune response. Based on these observations, the combination of ipilimumab and bevacizumab was studied in a Phase I study (see Table 3).125 Among 22 patients evaluable for response, six (27%) PRs, one (5%) CR, and seven (32%) durable SDs were observed. Serial perfusion computed tomography scans showed a persistent decreased tumor blood flow, and post-treatment biopsies in twelve patients revealed activated vessel endothelium with extensive T-cell trafficking and nonproductive central angiogenesis. Clinical activity and correlative studies suggest additive to synergistic effects with the combination of ipilimumab and bevacizumab and that this combination merits further exploration.

**Inhibiting targets within the same pathway**

**Combined BRAF and MEK inhibition**

The most promising combination strategy under evaluation is the simultaneous inhibition of BRAF and MEK. Promising evidence derived from a BRAF V600E human melanoma xenograft model, illustrated that combined administration of BRAF inhibitor GSK2118436 (GSK436) and MEK inhibitor GSK1120212 (GSK212) lead to greater antitumor activity compared to either monotherapy and decreased incidence of the BRAF inhibitor induced hyper-proliferative skin lesions.125 In fact, a Phase I/II trial has been conducted with the combination of GSK436 and GSK212 in patients with tumors harboring V600 BRAF mutations, 93% (n = 101 patients) with advanced melanoma (see Table 3).125 Full monotherapy doses were tolerated in combination and the common adverse events included: pyrexia, rash, chills, nausea, vomiting, diarrhea, and fatigue. Grade 3 neutropenia and leukopenia were also observed in only three and two patients respectively. As predicted by the xenograft model the co-administration of a MEK inhibitor lowered the incidence of rash and hyper-proliferative skin lesions, presumably by GSK212 blocking the BRAF inhibitor-induced activation of the MAPK pathway in cells with a wild-type BRAF gene. Forty-one of 71 patients with advanced melanoma and no prior exposure to a BRAF inhibitor had objective responses. Of 24 patients that had previous BRAF inhibitor therapy, three had PRs. These results exemplify the fact that combination treatments targeting the same pathway may be tolerable, reduce mechanism-based toxicity, and potentially enhance activity.
Conclusion
Improvements in the understanding of the molecular underpinnings of melanoma have finally translated into targeted therapies that improved survival for patients with advanced melanoma. Ipilimumab and vemurafenib are now the first-line treatment options for patients. CTLA4, other immune modulatory antibodies, and vaccines may play a crucial role in initiating and maintaining a melanoma specific immune response. Vaccine development strategies may benefit most from combinations with novel immune modulating monoclonal antibodies. In early Phase clinical trials of small molecule kinase inhibitors, there has been some significant antitumor activity identified in unique molecular subsets of melanoma patients. Research is currently focused on understanding the mechanisms of intrinsic and acquired resistance to these agents. These advances will lead to rationally designed combinations of first- and second-line therapies that will hopefully improve efficacy and tolerability in selected groups of melanoma patients.

Disclosure
The authors report no conflicts of interest in this work.

References
1. American Cancer Society. Cancer Facts and Figures 2011. 2011:1–60. Available from: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2011. Accessed January 16, 2012.
2. Canadian Cancer Society. Canadian Cancer Statistics 2011. 2011:1–133. Available from: http://www.cancer.ca. Accessed January 16, 2012.
3. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635–3648.
4. De Vita V, Hellman S, Rosenberg S. Biologic Therapy of Cancer: Melanoma. Philadelphia, PA: Lippincott; 1995:388–411.
5. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6 Suppl 1:S11–S14.
6. Cipponi A, Weers G, van Baren N, Coulie PG. Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother. 2011;60(8):1153–1160.
7. Hadrup SR, Bakker AH, Shu CJ, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods. 2009;6(7):520–526.
8. Kallilis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 2009;19(5):275–282.
9. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother. 2004;53(10):844–854.
10. Krassagasik K, Thölk D, Farthmann B, et al. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer. 1998;77(9):1492–1494.
11. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358(25):2698–2703.
36. Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. *Cancer Metastasis Rev.* 2005;24(2):273–285.

37. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. *Cancer Res.* 2004;64(19):7002–7010.

38. Zhou XP, Gimn O, Hampel H, et al. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. *Am J Pathol.* 2000;157(4):1123–1128.

39. Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. *J Cell Sci.* 2001;114(Pt 13):2375–2382.

40. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. *Front Biosci.* 2005;124(4):528–536.

41. Meier F, Schittek B, Busch S, et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. *Front Biosci.* 2005;10:2986–3001.

42. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. *Cancer Res.* 2008;68(9):3429–3439.

43. Hemesath TJ, Price ER, Takamoto C, Badalain T, Fisher DE. MAP kinase links the transcription factor Microphthalmia to c-Kit signaling in melanocytes. *Nature.* 1998;391(6664):298–301.

44. Roskoski Jr. Structure and regulation of Kit protein-tyrosine kinase – the stem cell factor receptor. *Biochem Biophys Res Commun.* 2005;338(3):1307–1315.

45. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. *New Eng J Med.* 2005;353(20):2135–2147.

46. Slipicevic A, Holm R, Nguyen MT, et al. Expression of activated Akt and mutant PTEN in malignant melanomas: relationship with clinical outcome. *Am J Clin Pathol.* 2005;124(4):528–536.

47. Whiteman DC, Zhou XP, Cummings MC, et al. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. *Int J Cancer.* 2002;99(1):63–67.

48. Wu H, Goel V, Halaska FG. PTEN signaling pathways in melanoma. *Oncogene.* 2003;22(26):3113–3122.

49. Roskoski R Jr. Structure and regulation of Kit protein-tyrosine kinase – the stem cell factor receptor. *Biochem Biophys Res Commun.* 2005;338(3):1307–1315.

50. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. *N Engl J Med.* 2005;353(20):2135–2147.

51. Ashida A, Takata M, Murata H, Kido K, Saida T. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. *Clin Cancer Res.* 2009;15(8):2375–2382.

52. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med.* 2010;363(9):809–819.

53. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. *Cir Opin Oncol.* 2011;23(2):177–182.

54. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. *J Clin Oncol.* 2009;27(3):e59–e61.

55. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. *Cell.* 2010;140(2):209–221.

56. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. *Nature.* 2010;464(7287):431–435.

57. Poulakis PL, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. *Nature.* 2010;464(7287):427–430.

58. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. *Nature.* 2010;468(7326):968–972.

59. Paraiso KH, Xiang Y, Rebecca VW, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. *Cancer Res.* 2011;71(7):2750–2760.

60. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. *Nature.* 2010;468(7326):973–977.

61. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/Pi3k. *Cancer Cell.* 2010;18(6):683–695.

62. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. *J Clin Oncol.* 2011;29(22):3085–3096.

63. Romano E, Schwartz GK, Chapman PB, Wolchok JD, Carvajal RD. Treatment implications of the emerging molecular classification system for melanoma. *Lancet Oncol.* 2011;12(9):913–922.

64. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract]. *ASCO Annual Meeting.* 2010;8503.

65. Ahmed T, Marais R, Pyle L, et al. BRAF 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Research.* 2004;64(19):7099–7109.

66. Advani L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. *Methods Enzymol.* 2006;407:597–612.

67. Ahmed T, Marais R, Pyle L, et al. BRAF 43-9006 in patients with advanced melanoma: The Royal Marsden experience [abstract]. *ASCO Annual Meeting.* 2004;7506.

68. Eisen T, Flaherty T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. *Br J Cancer.* 2006;95(5):581–586.

69. Flaherty K, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma [abstract]. *ASCO Annual Meeting.* 2004;7507.

70. Flaherty KT, Lee SJ, Schuchter LM, et al. Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma [abstract]. *ASCO Annual Meeting.* 2010;8511.

71. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. *J Clin Oncol.* 2009;27(17):2823–2830.

72. Sharmaf WH, Hodi FS, Lawrence DP, et al. Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma [abstract]. *ASCO Annual Meeting.* 2011;8508.

73. Solit DB, Garraway LA, Pratillas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. *Nature.* 2006;439(7074):358–362.

74. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. *Cancer Res.* 2010;70(2):1924–1937.

75. Boasberg PD, Redfern CH, Daniels GA, et al. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. *Cancer Chemother Pharmacol.* 2011;68(2):547–552.
80. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011;17(5):989–1000.

81. Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212 [abstract]. ASCO Annual Meeting. 2010:2503.

82. Veh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142866 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13(4):1576–1583.

83. Dummer R, Robert C, Chapman PB, et al. AZD6244 (ARRY-142866) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study [abstract]. ASCO Annual Meeting. 2008:9033.

84. Dry JR, Pavey S, Pratillas C a, et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 2010;70(6):2264–2273.

85. Pratillas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Nat Acad Sci U S A. 2009;106(11):4519–4524.

86. Ernst DS, Eisenhauer E, Wainman N, et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs. 2005;23(6):569–575.

87. Burris HA, Siu LL, Infante JR, et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study [abstract]. Asco Annual Meeting. 2011:3003.

88. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Nat Acad Sci U S A. 2001;98(18):10314–10319.

89. Schmelzel T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103(2):253–262.

90. Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Bio Chem. 2004;279(4):2737–2746.

91. Margolin K, Longmate J, Baratta T, et al. CCI-777 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005;104(5):1045–1048.

92. Rao RD, Windschitl HE, Allred JB, et al. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma [abstract]. 2005:8043.

93. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol. 2007;25(12):1606–1620.

94. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidine-4-yl)aminothiazole-5-carboxamide (BMS-354825), a dual Src/Abl inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. J Med Chem. 2004;47(27):6658–6661.

95. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037.

96. Kalinsky K, Lee SJ, Lawrence DP, Kirkwood JM. A phase II trial of dasatinib in advanced melanoma. Cancer. 2011;117(10):2202–2208.

97. Pomplun M, Schöfer T, Zeman B, et al. PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Nat Acad Sci U S A. 2011:3003.

98. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol. 2007;25(12):1606–1620.

99. von Mehren M. Beyond imatinib: second generation c-KIT inhibitors in metastatic melanoma. Br J Cancer. 2005;92(8):1398–1405.

100. Novartis Pharmaceuticals. A study of AMNN107 in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation [abstract]. ASCO Annual Meeting. 2009;2503.

101. Samsung Medical Center. Study of nilotinib in metastatic melanoma [abstract]. ASCO Annual Meeting. 2009:9026.

102. Institute of Cancer Research, United Kingdom. A trial looking at nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sun damaged melanoma. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2008 [updated October 27, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01168050. NLM identifier: NCT01168050. Accessed February 8, 2012.

103. Samsung Medical Center. Study of nilotinib in metastatic melanoma [abstract]. ASCO Annual Meeting. 2009:9026.

104. Samsung Medical Center. Study of nilotinib in metastatic melanoma with KIT aberrations. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated January 10, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01099514. NLM identifier: NCT01099514. Accessed February 8, 2012.

105. Kluger HM, Dudek AZ, McCann C, et al. A phase 2 trial of dasatinib in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904–2909.

106. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904–2909.

107. Assistance Publique – Hôpitaux de Paris. Efficacy of nilotinib in first or second line treatment of primary melanomas stage III unresectable melanomas. (NILOMEL). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated August 11, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00788775. NLM identifier: NCT00788775. Accessed February 8, 2012.

108. Bayer HealthCare. Study of nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sun damaged melanoma. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated July 14, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01359121. NLM identifier: NCT01359512. Accessed February 8, 2012.

109. Courtney KL, O’Hara P, Pritchard J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327–2334.

110. von Mehren M. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin Colorectal Cancer. 2006;6 Suppl 1:S30–S34.
116. Lipton A, Ready N, Bukowski RM, et al. Phase I study of continuous oral lonafarnib plus weekly paclitaxel for advanced cancer [abstract]. ASCO Annual Meeting. 2002:364.

117. Zuewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000;18(4):927–941.

118. Hong DS, Sebti SM, Newman RA, et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009;15(22):7061–7068.

119. Margolin KA, Moon J, Flaherty LE, et al. Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPi) in metstatic melanoma: Southwest Oncology Group Trial S0438 [abstract]. ASCO Annual Meeting. 2010:8502.

120. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001;19(2):577–583.

121. Hainsworth JD, Spigel DR, Burris 3rd HA, et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010;28(13):2131–2136.

122. Hainsworth JD, Infante JR, Spigel DR, et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010;116(17):4122–4129.

123. Kruit WH, Suciu S, Dreno B, et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032-18031) [abstract]. ASCO Annual Meeting. 2009:9065.

124. Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718–730.

125. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18(4):927–941.

126. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–3175.

127. Sznol M, Hodis F, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) [abstract]. ASCO Annual Meeting. 2008:3007.

128. Kruit WH, Suciu S, Dreno B, et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032-18031) [abstract]. ASCO Annual Meeting. 2008:9065.

129. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–5771.

130. McDermott DF, Sosman JA, Gonzalez R, et al. Double-blind randomized phase II study of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Cancer Res. 2007;13(6):1801–1809.

131. Hainsworth JD, Infante JR, Spigel DR, et al. Bevacizumab and everolimus in patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010;116(17):4122–4129.

132. Recently published authors.

133. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–5771.

134. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res. 2007;13(6):1801–1809.

135. Hauschild A, Gutzmer R, Ugurel S, et al. Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Ann Oncol. 2011;22(7):1667–1674.

136. Eisen T, Marais R, Affolter A, et al. An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma [abstract]. ASCO Annual Meeting. 2007:8529.